Three Or More Saccharide Radicals (e.g., Neomycin, Etc.) Patents (Class 514/39)
  • Patent number: 11376217
    Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: July 5, 2022
    Assignee: Cristcot LLC
    Inventors: Jennifer J. Davagian, Raj Devarajan
  • Patent number: 11369625
    Abstract: An object of the present invention is to provide an anti-tumor agent and an anti-tumor kit which have superior anti-tumor effect as compared with a therapy with gemcitabine, paclitaxel or a combination thereof; as well as an anti-tumor effect enhancer. According to the present invention, provided is an anti-tumor agent including paclitaxel or a salt thereof and 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl)cytosine or a salt or prodrug thereof.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 28, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Yoshihide Iwaki, Tsukasa Kitahashi, Shinji Mima
  • Patent number: 10434144
    Abstract: Provided herein are methods of using 7a-hydroxy-4-cholsten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 8, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Alexander Mark Depaoli, Jian Luo, Hui Tian
  • Patent number: 9744210
    Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with a corticosteroid.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: August 29, 2017
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventor: Benjamin S. Bleier
  • Patent number: 9556196
    Abstract: The present invention relates to a use of haloid acid salt and sulfonate of a compound of formula I and a salt of the compound of formula I in preparation of medicament for preventing or treating diseases caused by thrombosis or embolism. The present invention provides acid addition salts, especially haloid acid and sulfonic acid addition salts of a compound of formula I having high inhibition effect on platelet aggregation, and preparation method of the same, a medicament comprising the same, and a use and/or method for preventing or treating diseases caused by thrombosis or embolism.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: January 31, 2017
    Assignee: GUANGZHOU HEERSHI PHARMA DEVELOPMENT CO., LTD
    Inventor: Xiaojing Yan
  • Patent number: 9180126
    Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: November 10, 2015
    Assignee: Mylan Specialty L.P.
    Inventor: Imtiaz Chaudry
  • Publication number: 20150099713
    Abstract: Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufactiurc of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 9, 2015
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Mark Pimentel, Henry C. Lin
  • Patent number: 8999942
    Abstract: In some aspects, the present invention provides aminoglycoside derivatives thereof that exhibit antibacterial activity. In some aspects, the aminoglycoside derivatives comprise compounds consisting of (a) an ammoglycoside group and (b) at least one hydrophobic carbamate and alkoxy group to the primary or secondary hydroxy position of the aminolvcoside group and salts thereof. Additionally, methods of treating and preventing bacterial infections using the aminoglycoside derivatives are also provided.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: April 7, 2015
    Assignee: University of Manitoba
    Inventors: Frank Schweizer, Smritilekha Bera, George Zhanel
  • Publication number: 20150087611
    Abstract: A multi-step stabilization method for connective tissue is described. Stabilized tissues can exhibit increased resistance to degradation due to enzyme activity, fatigue and storage. The multi-step method includes a first step during which the tissue can be incubated with a glycosaminoglycanase inhibitor, a second step during which the tissue can be incubated with a crosslink activator and/or a phenolic compound, and a third step during which the tissue can be incubated with a second crosslink activator.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Inventors: Naren Vyavahare, Hobey Tam
  • Publication number: 20150080329
    Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DHA, EPA and/or GLA, used in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin or ocular infection.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Mehar Manku, John Climax, Jonathan Rowe
  • Publication number: 20150038441
    Abstract: The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal.
    Type: Application
    Filed: December 21, 2011
    Publication date: February 5, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Joachim Karle, Reinhard Seffner
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20140356457
    Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test com
    Type: Application
    Filed: April 7, 2014
    Publication date: December 4, 2014
    Applicant: UNIVERSITY OF GENEVA
    Inventors: Karl-Heinz KRAUSE, Botond BANFI
  • Publication number: 20140357591
    Abstract: Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerged thereagainst, as well as processes for preparation the same, compositions containing the same, and uses thereof in medical treatments against pathogenic microorganisms. The disclosed antimicrobial conjugates are composed of aminoglycosides and non-ribosomal active antibiotics. Some of the antimicrobial conjugates are prepared via “click” chemistry.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Timor BAASOV, Varvara Pokrovskaya, Valery Belakhov, Mariana Hainrichson
  • Patent number: 8889733
    Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: November 18, 2014
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul Wahab, Christian D. A. Fozing, Atta-ur Rahman
  • Publication number: 20140328896
    Abstract: Provided are methods and compositions for enhancing the gastrointestinal health of an animal in need thereof by administering a gastrointestinal health maintaining or improving amount of a composition comprising an effective amount of lactic acid. The administered composition may also comprise one or more prebiotic, probiotic, symbiotic, anti bacterial, or anti-diarrhea agents.
    Type: Application
    Filed: December 29, 2011
    Publication date: November 6, 2014
    Applicant: HILL'S PET NUTRITION, INC.
    Inventors: Dennis Jewll, Luis J. Montelongo, Sarah Martinez, Lynda Melendez
  • Publication number: 20140323422
    Abstract: The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventors: Warren Charles KETT, Yugang CHEN
  • Patent number: 8865664
    Abstract: Hydrophobically enhanced aminoglycosides have been prepared and shown to be effective antibacterial agents. These agents may be used in the treatment or prevention of various bacterial infections. Methods of preparing these agents also permit facile synthetic access. Formula (I).
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: October 21, 2014
    Assignee: University of Manitoba
    Inventors: Smritilekha Bera, George G. Zhanel, Frank Schweizer
  • Publication number: 20140271923
    Abstract: Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventor: Christopher Brian Reid
  • Publication number: 20140248298
    Abstract: Bioactive agents are delivered to a body site in need of the same by providing a first aliquot portion of a reaction mixture which includes an aldehydic polymer solution, and a second aliquot portion of a reaction which includes a cross-linking hydrazide and a bioactive agent. The first and second aliquot portions may be mixed (e.g., by expelling such portions from respective syringe barrels) to form the reaction mixture thereof. The thus formed reaction mixture may then be installed at the body site whereby the reaction mixture is allowed to solidify in situ within about 1 to 10 minutes into a reaction product comprised of a hydrazide cross-linked oxidized aldehydic polymer matrix with the bioactive agent entrapped therein.
    Type: Application
    Filed: February 26, 2014
    Publication date: September 4, 2014
    Applicant: ROYER BIOMEDICAL, INC.
    Inventor: Garfield P. ROYER
  • Publication number: 20140243280
    Abstract: The invention relates to drug development and synthetic chemistry, in particular to the manufacture of biologically active compounds based on naturally occurring molecules. It also relates to novel biologically active compounds, for example aminoglycoside antibiotics, in a substantially pure regioisomeric form.
    Type: Application
    Filed: June 14, 2012
    Publication date: August 28, 2014
    Applicant: Rijksuniversiteit Groningen
    Inventors: Andreas Herrmann, Andreas Alexander Bastian, Alessio Marcozzi
  • Patent number: 8809286
    Abstract: Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerged thereagainst, as well as processes for preparation the same, compositions containing the same, and uses thereof in medical treatments against pathogenic microorganisms. The disclosed antimicrobial conjugates are composed of aminoglycosides and non-ribosomal active antibiotics. Some of the antimicrobial conjugates are prepared via “click” chemistry.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: August 19, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Timor Baasov, Varvara Pokrovskaya, Valery Belakhov, Mariana Hainrichson
  • Publication number: 20140227375
    Abstract: Interaction of a specific viral domain with phosphatidylinositol 4,5-bisphosphate (PIP-2) is shown to mediate viral replication. Basic Amino Acid PIP-2 Pincer (BAAPP) domains are described herein, including, without limitation, NS5A protein of HCV, NS4B protein of HCV, poliovirus, and rhinovirus.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 14, 2014
    Inventors: Jeffrey S. Glenn, Phillip S. Pang, Nam-Joon Cho, Choongho Lee
  • Patent number: 8802707
    Abstract: This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis Cancers. These very tiny L-form Cell-Wall-Deficient (CWD) antibiotic-resistant bacteria live within the cytoplasm of cells, including the phagocytic cells (e.g. monocytes, macrophages, lymphocytes, neutrophils and polymorphonuclear cells) of the immune system itself. The cellular proliferation in Cancer is catalysed the action of the same tiny L-form bacteria. They cause the cell nucleus to release mRNA signaling the Th1 cytokine cascade without the need for conventional signaling via, for example, CD4+T -Lymphocytes. Some of these Cytokines and Chemokines, including, without limitation, Cellular Adhesion Molecule (CAM), create the environment which allows the cellular proliferation to start, and then allows the cancerous growth to gain a foothold in the body. Killing these stealthy pathogens removes the environment needed to initiate and feed the cellular proliferation commonly called ‘Cancer’.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: August 12, 2014
    Inventor: Trevor Gordon Marshall
  • Publication number: 20140206636
    Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
    Type: Application
    Filed: September 12, 2013
    Publication date: July 24, 2014
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Henry C. Lin, Mark Pimentel
  • Publication number: 20140206637
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Application
    Filed: June 13, 2012
    Publication date: July 24, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Publication number: 20140200189
    Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.
    Type: Application
    Filed: January 14, 2013
    Publication date: July 17, 2014
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul-Wahab, Christian D.A. Fozing
  • Publication number: 20140171358
    Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used alone or in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin infection or wound healing.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: Dignity Sciences Limited
    Inventors: Mehar Manku, John Climax, Jonathan Rowe, David Coughlan
  • Patent number: 8734831
    Abstract: A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor includes (a) forming a porous ceramic scaffold; (b) mixing a silica xerogel and a physiologically active organic substance in a volumetric ratio ranging from 30:70 to 90:10 and treating by a sol gel method to prepare an organic/inorganic hybrid composite solution; (c) adding a bioactive factor to the organic/inorganic hybrid composite solution and agitating until gelation occurs; and (d) coating the porous ceramic scaffold with the organic/inorganic composite containing the bioactive factor added thereto. In accordance with the method, the porous ceramic scaffold may be uniformly coated with the organic/inorganic hybrid composite while maintaining an open pore structure, and stably discharge the bioactive factor over a long period of time.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: May 27, 2014
    Assignee: SNU R&DB Foundation
    Inventors: Hyoun-Ee Kim, Shin-Hee Jun, Eun-Jung Lee
  • Publication number: 20140127320
    Abstract: A composition and method adapted for delivery of hydrophilic, biologically-active agents are disclosed. The composition can include a reverse microemulsion formed from at least one hydrophilic, biologically-active agent solubilized by a hydrophobic reverse emulsion surfactant in a non-stinging, volatile, hydrophobic solvent. The non-stinging, volatile, hydrophobic solvent is selected from the group consisting of volatile linear and cyclic siloxanes, volatile linear, branched, and cyclic alkanes, volatile fluorocarbons and chlorofluorocarbons, liquid carbon dioxide under pressure, and combinations thereof. The reverse microemulsion can be an optically clear solution.
    Type: Application
    Filed: October 21, 2013
    Publication date: May 8, 2014
    Applicant: ROCHAL INDUSTRIES, LLP
    Inventors: Joseph Charles Salamone, Xiaoyu Chen, Ann Beal Salamone, Katelyn Elizabeth Reilly
  • Patent number: 8715623
    Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 6, 2014
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
  • Publication number: 20140088032
    Abstract: The invention relates to a veterinary composition for intramammary administration comprising a combination of an antibacterial agent and a Toll-Like-Receptor (TLR) agonist and to the use of said composition for the treatment of mastitis in lactating ruminants.
    Type: Application
    Filed: May 11, 2012
    Publication date: March 27, 2014
    Inventors: Thomas Simon Ilg, Ralf Warrass, Peter Gerardus Franciscus Cox, Carlos De Sa, Karine Pere
  • Patent number: 8679532
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: March 25, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Patent number: 8673349
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 18, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Patent number: 8673348
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 18, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Patent number: 8653041
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: February 18, 2014
    Assignee: Achaogen, Inc.
    Inventors: Adam Aaron Goldblum, Paola Dozzo, Timothy Robert Kane, James Bradley Aggen, Martin Sheringham Linsell, Darin James Hildebrandt, Micah James Gliedt
  • Publication number: 20140038914
    Abstract: This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.
    Type: Application
    Filed: January 17, 2012
    Publication date: February 6, 2014
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Karine Auclair, Kenward Vong
  • Publication number: 20140037709
    Abstract: A system for the protection against degradation during pelleting of one or more physiologically or pharmacologically active substances, comprising compositions in the form of micro particles or granules, particularly for use in the zootechnical and/or veterinary field. The micro particles include a core which contains one or more substances having a pharmacological action, food supplements or diagnostic media, said one or more substances being characterized by the presence, within their chemical structure, of a basic functional group, specifically including an amine functional group. The core comprises also one or more carboxylic acids and/or their salts and eventually one or more excipients. Said core is coated by an outer layer of fats or waxes, and preferably by a mixture of glyceride of fatty acids.
    Type: Application
    Filed: August 2, 2013
    Publication date: February 6, 2014
    Applicant: Kemin Industries, Inc.
    Inventors: Sarah E. Boucher, Jill Davidson, Bill L. Miller
  • Patent number: 8642075
    Abstract: A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: February 4, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Patent number: 8632804
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: January 21, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Publication number: 20130287866
    Abstract: Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation.
    Type: Application
    Filed: October 26, 2011
    Publication date: October 31, 2013
    Applicant: ORAL DELIVERY TECHNOLOGY LTD.
    Inventor: Michael Farber
  • Patent number: 8546343
    Abstract: The present invention relates to paromamine-based compounds according to formula I having selective antimicrobial activity directed at ribosomal 16S RNA. Furthermore, the invention is directed to the use of said compounds for preparing a medicament, pharmaceutical preparations and methods for preparing said compounds.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: October 1, 2013
    Assignees: Eidgenoessische Technische Hochschule Zurich, Uiniversitat Urich Prorektorat Forschung
    Inventors: Erik C. Boettger, Andrea Vasella, Deborah Perez Fernandez
  • Publication number: 20130237485
    Abstract: This invention discloses a method of inducing expression of full-length collagen 7 in cells that contain nonsense mutations in the COL7A1 gene by treating the cell with an aminoglycoside such as G418, gentamicin, and paromomycin. Also provided is a method of treating DEB due to nonsense mutation in the COL7A1 gene by administering a composition containing an effective amount of an aminoglycoside. Also provided is a novel composition useful to treating conditions due to nonsense mutation in the COL7A1 gene, containing an aminoglycoside, a C7, a min-C7 or both; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 6, 2011
    Publication date: September 12, 2013
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Mei Chen, David Woodley
  • Publication number: 20130224258
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Application
    Filed: February 12, 2013
    Publication date: August 29, 2013
    Applicant: MICROBION CORPORATION
    Inventor: Microbion Corporation
  • Publication number: 20130217620
    Abstract: The present invention relates to ionic silicone hydrogel contact lenses which comprise at least one pharmaceutical or nutriceutical component and are formed from reaction mixtures comprising a mixture of slow-reacting hydrophilic monomers, including at least one slow-reacting ionic monomer, at least one silicone-containing component and at least one hydroxyl-containing component, wherein the ratio of the slow-reacting hydrophilic component half lives to the silicone-containing component half life is at least 2.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 22, 2013
    Applicant: Johnson & Johnson Vision Care, Inc.
    Inventor: Johnson & Johnson Vision Care, Inc.
  • Patent number: 8507454
    Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: August 13, 2013
    Assignee: Novartis AG
    Inventors: Robert J Speirs, Barbara A Schaeffler, Peter B Challoner
  • Publication number: 20130184230
    Abstract: This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with another antimicrobial agent selected from the group consisting of a beta-lactam antimicrobial agent, mupirocin and chlorhexidine or a pharmaceutically acceptable derivative thereof, for the prevention and/or treatment of microbial infections.
    Type: Application
    Filed: August 5, 2011
    Publication date: July 18, 2013
    Applicant: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony R.M. Coates
  • Publication number: 20130178438
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: October 15, 2012
    Publication date: July 11, 2013
    Applicant: ACHAOGEN, INC.
    Inventor: Achaogen, Inc.
  • Patent number: 8481502
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: July 9, 2013
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Paola Dozzo, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Micah James Gliedt, Martin Sheringham Linsell
  • Patent number: RE47034
    Abstract: Embodiments of topical formulations for administering compound I or a pharmaceutically acceptable salt or solvate thereof are disclosed. Embodiments of methods for using the topical formulations in the treatment of dermatological disorders such as cutaneous collagen vascular diseases, e.g., cutaneous lupus, also are disclosed.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 11, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Thomas Sun, Matt Duan